Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
November 24 2023 - 6:30AM
Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on
November 16, 2023, the New York Stock Exchange (NYSE) sent a notice
that the company is not in compliance with Section 802.01E of the
NYSE Listed Company Manual due to a delay in filing its Quarterly
Report on Form 10-Q for the quarter ended September 30, 2023 with
the Securities and Exchange Commission (SEC). Notices are
routinely issued by the NYSE in such situations.
Under the NYSE’s rules, Emergent will have six months from
November 9, 2023 to file the Form 10-Q with the SEC, and can regain
compliance with the NYSE listing standards upon filing the Form
10-Q.
As previously disclosed in the Company’s Form 12b-25 filed with
the SEC on November 9, 2023, the Company is working to quantify and
evaluate the impact to its reporting regarding past period state
deferred tax liability and income tax benefits. Because these items
also affect subsequent period reporting, the Company must complete
this work prior to finalizing its financial statements for the
three and nine months ended September 30, 2023 and filing its third
quarter Form 10-Q. Emergent is unable to provide a complete
estimate of its results of operations for the three- and nine-month
periods ended September 30, 2023 while it finalizes the state tax
adjustments referenced above. In addition, Emergent is continuing
to assess the impact of these adjustments on prior periods and
accordingly is unable to provide a comparison of its current
results to the three- and nine-month periods ended September 30,
2023.
About Emergent BioSolutions At
Emergent, our mission is to protect and enhance life. For 25 years,
we’ve been at work defending people from things we hope will never
happen—so we are prepared just in case they ever do. We provide
solutions for complex and urgent public health threats through a
portfolio of vaccines and therapeutics that we develop and
manufacture for governments and consumers. We also offer a range of
integrated contract development and manufacturing services for
pharmaceutical and biotechnology customers. To learn more about how
we plan to protect or enhance 1 billion lives by 2030, visit
our website and follow us on LinkedIn, Twitter,
and Instagram.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical fact, including statements
regarding the future performance of the Company or our business
strategy, future operations, future financial position, future
revenues and earnings, our ability to achieve the objectives of our
restructuring initiatives, including our future results, projected
costs, prospects, plans and objectives of management, are
forward-looking statements. We generally identify forward-looking
statements by using words like “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “forecast,” “future,” “goal,”
“intend,” “may,” “plan,” “position,” “possible,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would,” and
similar expressions or variations thereof, or the negative thereof,
but these terms are not the exclusive means of identifying such
statements. Forward-looking statements are based on our current
intentions, beliefs and expectations regarding future events based
on information that is currently available. We cannot guarantee
that any forward-looking statement will be accurate. Readers should
realize that if underlying assumptions prove inaccurate or if known
or unknown risks or uncertainties materialize, actual results could
differ materially from our expectations. Readers are, therefore,
cautioned not to place undue reliance on any forward-looking
statement. Any forward-looking statement speaks only as of the date
of this press release, and, except as required by law, we do not
undertake any obligation to update any forward-looking statement to
reflect new information, events or circumstances.
Investor Contact:Richard S. LindahlExecutive
Vice President, CFOlindahlr@ebsi.com
Media Contact:Assal HellmerVice President,
Communicationsmediarelations@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2024 to May 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From May 2023 to May 2024